[POLYMORPHISM OF CYP2C9 GENE AND RISK OF HEPATOTOXICITY DEVELOPMENT DURING ANTIRETROVIRAL THERAPY.]

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

[POLYMORPHISM OF CYP2C9 GENE AND RISK OF HEPATOTOXICITY DEVELOPMENT DURING ANTIRETROVIRAL THERAPY.]

Eksperimental'naia i klinicheskaia farmakologiia - 1 Jan 2016

Kurbat M N, Tsyrkunov V M, Stepuro T L

Abstract excerpt

We have studied the association of polymorphic variants of CYP2C9 genes with the risk of drug-induced liver injury (DILI) during antiretroviral therapy of HIV-infected patients. The analysis of polymorphic variants of CYP2C9*2.(Argl44Cys) and CYP2C9*3 (Ile359Leu) genes showed that the dominant genotype of CYP2C9*2 was the honiozygous CC carriership and for CYP2C9*3 it was the prevalence of AA genotype, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Anti-Retroviral Agents
Share to Chemical and Drug Induced Liver Injury
Share to Cytochrome P-450 CYP2C9
Share to Genotype
Share to HIV-1
Share to HIV Infections
Share to Polymorphism, Genetic

Source

Open in PubMed

Identifiers

PMID: 29787666

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics